Reply:
Carlos M. Rodriguez‐Ortigosa, Fernando Corrales, Juan F. Medina, Jesús Prieto – 7 September 2010
Treatment of acute hepatitis C in human immunodeficiency virus–infected patients: The HEPAIG study
Lionel Piroth, Christine Larsen, Christine Binquet, Laurent Alric, Isabelle Auperin, Marie‐Laure Chaix, Stéphanie Dominguez, Xavier Duval, Anne Gervais, Jade Ghosn, Elisabeth Delarocque‐Astagneau, Stanislas Pol – 7 September 2010 – Acute hepatitis C continues to be a concern in men who have sex with men (MSM), and its optimal management has yet to be established.
Small‐duct sclerosing cholangitis associated with Schistosoma mansoni
Catherine H. McCrann, James L. Boyer – 7 September 2010
Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells
Mei‐Chuan Chen, Chun‐Han Chen, Hsiao‐Ching Chuang, Samuel K. Kulp, Che‐Ming Teng, Ching‐Shih Chen – 7 September 2010 – Histone deacetylase (HDAC) inhibitors exhibit a unique ability to degrade topoisomerase (topo)IIα in hepatocellular carcinoma (HCC) cells, which contrasts with the effect of topoII‐targeted drugs on topoIIβ degradation. This selective degradation might foster novel strategies for HCC treatment in light of the correlation of topoIIα overexpression with the aggressive tumor phenotype and chemoresistance.
Observed and calculated interleukin‐28B genotype frequencies in hepatitis C virus infection
Magnus Lindh, Martin Lagging, Gunnar Norkrans, Kristoffer Hellstrand – 7 September 2010
The next step for taribavirin
Paul Y. Kwo, Rakesh Vinayek – 7 September 2010
Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection
Martin Lagging, Åsa Alsiö, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Kristoffer Hellstrand, Gunnar Norkrans – 7 September 2010
On the mechanism of action of vitamin E for nonalcoholic steatohepatitis
Hong‐Fang Ji, Liang Shen – 1 September 2010
Reply:
Michael P. Manns, Albert J. Czaja, James D. Gorham, Edward L. Krawitt, Giorgina Mieli‐Vergani, Diego Vergani, John M. Vierling – 1 September 2010
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
Yun‐Fan Liaw, I‐Shyan Sheen, Chuan‐Mo Lee, Ulus Salih Akarca, George V. Papatheodoridis, Florence Suet‐Hing Wong, Ting‐Tsung Chang, Andrzej Horban, Chia Wang, Peter Kwan, Maria Buti, Martin Prieto, Thomas Berg, Kathryn Kitrinos, Ken Peschell, Elsa Mondou, David Frederick, Franck Rousseau, Eugene R. Schiff – 1 September 2010 – Data are limited on the safety and effectiveness of oral antivirals other than lamivudine and adefovir dipivoxil for treatment of chronic hepatitis B (CHB) in patients with decompensated liver disease.